Calvo J, et al. (1998) Human CD5 signaling and constitutive phosphorylation of C-terminal serine residues by casein kinase II. J Immunol 161, 6022-9 9834084

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S482-p - CD5 (human) ▲

Modsite: SsMQPDNssDsDyDL SwissProt Entrez-Gene Orthologous residues CD5 (human): S482‑p, CD5 (mouse): S481‑p, CD5 (rat): S478‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte) [CD5 (human)] Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK2A1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes heparin sodium decrease phorbol_ester increase heparin sodium phorbol_ester inhibit treatment-induced increase

S483-p - CD5 (human) ▲

Modsite: sMQPDNssDsDyDLH SwissProt Entrez-Gene Orthologous residues CD5 (human): S483‑p, CD5 (mouse): S482‑p, CD5 (rat): S479‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte) [CD5 (human)] Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK2A1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes heparin sodium decrease phorbol_ester increase heparin sodium phorbol_ester inhibit treatment-induced increase

S485-p - CD5 (human) ▲

Modsite: QPDNssDsDyDLHGA SwissProt Entrez-Gene Orthologous residues CD5 (human): S485‑p, CD5 (mouse): S484‑p, CD5 (rat): S481‑p Characterization Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site Disease tissue studied:  Fanconi's anaemia Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte) [CD5 (human)] Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK2A1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes heparin sodium decrease phorbol_ester increase heparin sodium phorbol_ester inhibit treatment-induced increase